



ACT Group Therapy for Health Anxiety



Lisbeth Frostholm, Psychologist, Ph. D. <u>lisbfros@rm.dk</u> Ditte Hoffmann Jensen, Psychologist, <u>dittjese@rm.dk</u>

Trine Eilenberg Louise Kronstrand Per Fink





Program

- 1. Definitions of health anxiety
- 2. Results from a pilot study
- 3. Preliminary results from a RCT.
- 4. Next step: Internet-delivered ACT





Article

A New, Empirically Established Hypochondriasis Diagnosis

Eva Ørnbøl, M.Sc.
Tomas Toft, M.D.
Kaj Christensen Sparle, M.D., Ph.D.
Lisbeth Frostholm, M.Sc.

Per Fink M.D. Ph.D. D.M.Sc

Frede Olesen, D.M.Sc., M.D.

Objective: The narrow ICD-10 and DSM-IV definition of hypochondriasis makes it rarely used yet does not prevent extensive diagnosis overlap. This study identified a distinct hypochondriasis symptom cluster and defined diagnostic criteria.

Method: Consecutive patients (N=1,785) consulting primary care physicians for new illness were screened for somatization, anxiety, depression, and alcohol abuse. A stratified subgroup of 701 patients were interviewed with the Schedules for Clinical Assessment in Neuropsychiatry and questions addressing common hypochondriasis symptoms. Symptom patterns were analyzed by latent class analysis.

Results: Patients fell into three classes based on six symptoms: preoccupation with the idea of harboring an illness or with bodily function, rumination about illness. suggestibility. unrealistic fear of infrequent in one of the classes. Classification allowed definition of new diagnostic criteria for hypochondriasis and division of the cases into "mild" and "severe." The weighted prevalence of severe cases was 9.5% versus 5.8% for DSM-IV hypochondriasis. Compared with DSM-IV hypochondriasis, this approach produced less overlap with other somatoform disorders, similar overlap with nonsomatoform psychiatric disorders, and similar assessments by primary care physicians. Severe cases of the new hypochondriasis lasted 2 or more years in 54.3% of the subjects and 1 month or less in 27.2%.


Conclusions: These results suggest that rumination about illness plus at least one of five other symptoms form a distinct diagnostic entity performing better than the current DSM-IV hypochondriasis diagnosis.

Fink et al Am J Psych 2004





A Model of Health Anxiety







Prevalence of health anxiety in primary care (n=701/1785)

Gender	Health anxiety % (CI 95%)
Males	9.3 (4.7-17.4)
Females	<mark>9.6</mark> (6.3-14.2)

Fink et al Am J Psych 2004

The Research Clinic for Functional Disorders and Psychosomatics





OPEN O ACCESS Freely available online



The Outcome of Health Anxiety in Primary Care. A Two-Year Follow-up Study on Health Care Costs and Self-Rated Health

Per Fink¹*, Eva Ørnbøl¹, Kaj Sparle Christensen²

1 The Research Clinic for Functional Disorders and Psychosomatics, Aarhus University Hospital, Aarhus, Denmark, 2 The Research Unit for General Practice, Aarhus University, Aarhus, Denmark

...the severe Health anxiety patients used about 41-78% more health care per year in total than patients presenting well-defined medical conditions,

.....and that spontaneous remission is rare





Primary outcome: The Whiteley-7 index – Illness worry

Not at all -----A great deal

1. Worries that there is something seriously wrong with your body?			х	
2. Worries that you suffer a disease you have read or heard about?				х
3. Many different pains or aches?			x	
4. Worries about the possibility of having a serious illness?		х		
5. Many different symptoms?			x	
6. Thoughts, that the doctor may be wrong if telling you not to worry?				х
7. Worries about your health?				х

I am seriously ill – no, I just worry – But how do I know for sure that the GP is right – he didn't even take blood tests!! STOP IT! – now my chest hurts again – how will my kids make it without me!





Acceptance and Commitment Group-Therapy for Health Anxiety

- -Results from a pilot study
- Aimed to investigate the
- 1. Feasibility
- 2. Mediators of change





Methods

- **Design:** Uncontrolled pilot study with self-report questionnaires at baseline, at end of treatment, and at 3- and 6-month follow-up.
- **Participants:** 34 patients (25 females) with severe health anxiety consecutively referred from general practitioners and hospitals departments
- **Treatment:** 10 sessions in four groups of 8-9 patients for 3.5 h administered by two psychologists.



Hopelessness

õ

N

Phase

Values and

Phase 3:

commited

action

Willingness

Defusion

Phase 1: Creative



Manual outline – 10 sessions

- 1) Introduction to the treatment program
- 2) What is ACT and mindfulness?
- 3) Creative hopelessness (Inflexible behavior/thoughts)
- 4) Control as the problem not the solution.
- 5) Willingness
- 6) Defusion from thoughts having a thought vs being your thoughts
- 7) Self-as-context you are more than your stories about yourself
- 8) Values clarification what is valuable for you?
- 9) Committed action

10) Booster session (how to maintain learned strategies)






Measures

- Primary outcome
 - Illness worry (Whiteley-7)
- Secondary outcome
 - Psychosocial measures:
 - Symptom load (SCL-SOM)
 - Emotional distress (SCL-8)
 - Process measures:
 - 'Psychological Flexibility' (AAQ-II)
 - 'Mindfulness' (FFMQ)





Outcome measures




The Research Clinic for Functional Disorders and Psychosomatics





Process measures







Primary and secondary outcome measures

Measures	Baseline	End of treatment		6-month	
	Mean (S.D.)	Mean (S.D.)	Cohens <i>d</i> (CI)	Mean (S.D.)	Cohens <i>d</i> (CI)
WI-7 (0-100)	67.2 (26.0)	40.6 (26.0)	1.20 ** (0.74;1.66)	34.5 (26.9)	1.32** (0.82;1.82)
AAQ (0-100)	44.8 (19.5)	57.0 (23.1)	0.76 * (0.35;1.17)	62.2 (23.8)	1.08 ** (0.61;1.55)
<i>FFMQ</i> (0-100)	50.3 (8.1)	55.8 (11.6)	0.55 * (0.16;0.94)	61.9 (15.0)	0.88** (0.45;1.31)

WI-7 = Whiteley-Index 7-item version; AAQ = Acceptance and Action Questionnaire; FFMQ = Five Facet Mindfulness Questionnaire; S.D. = standard deviation; <math>CI = Confidence Interval. Cohens *d* effect size: small 0.2-0.49, moderate 0.50-0.79, large 0.80-.

p*<0.05, *p*<0.01





Mediation analyses

Table B.1. Mediators of Health anxietysymptomsat 6 months	R ²	в	СІ	p	
Model 1: Health anxiety symptoms (WI-7(T4)) 1. WI-7(T1)	.34	.57	.26;.88	.001	
 Model 2: Health anxiety symptoms and psychological flexibility 1. WI-7(T1) 2. ΔΑΑQ(T2) 	.54	.47 70	.18;.75 -1.20;22	.003 .007	LR=8.49, <i>p</i> <0.05
Model 3: Health anxiety symptoms and mindfulness 1. WI-7(T1) 2. ΔFFMQ(T2)	.57	.56 1.17	.27;.84 -2.00;33	.001 .009	LR=8.09, <i>p</i> <0.05

Table B.1. Models of mediation.

WI-7 = Whiteley-Index 7-item version; AAQ = Acceptance and Action Questionnaire; FFMQ = Five Facet Mindfulness Questionnaire; (T1) = Pre-treatment; (T4) = 6-month follow-up; Δ (T2) = Changes from pre-treatment to post-treatment (T2-T1); R² = Coefficient of determination; B = Unstandardized regression coefficient; CI = Confidence interval.






Accepted Manuscript

Title: Acceptance and Commitment Group Therapy for Health Anxiety–results from a pilot study

Author: T. Eilenberg L. Kronstrand P.K. Fink L. Frostholm



PII:	S0887-6185(13)00120-5
DOI:	http://dx.doi.org/doi:10.1016/j.janxdis.2013.06.001
Reference:	ANXDIS 1513
To appear in:	Journal of Anxiety Disorders

 Received date:
 31-8-2012

 Revised date:
 3-5-2013

 Accepted date:
 1-6-2013





3. Preliminary results from a RCT

The Research Clinic for Functional Disorders and Psychosomatics





Preliminary results; - Satisfaction with treatment

- 83.1% (n=49) of the patients were extremely or very satisfied with the treatment

- 88.1% (n=49) would recommend the treatment to a friend,

- 80.7% (n=46) found that the treatment had improved their quality of life





Clinical challenges

- Increasing number of referrals
- Long waitlist
- Making our treatment accessible (few clinics offer specialized treatment for health anxiety)





Internet-delivered psychotherapy

- Internet-delivered CBT has shown effect on health anxiety (Hedman et al., 2011).
- The promising results from ACTbased "face-to-face" treatment indicate that I-ACT may be a feasible treatment.





Aim

- 1) To develop an I-ACT program for health anxiety based on the existing manual, and
- 2) examine the efficacy in a randomised controlled trial.



